Table 1.

CD10 expression status in different cancers.

Cancer	CD10 level	Prognosis	References
Prostate cancer	Decreased/total loss of CD10 expression	Androgen-independent progression	[48, 49]
Prostate cancer	High level of CD10	Aggressive phenotype, higher malignancy rate, larger metastases, early death	[33, 50]
Breast cancer	Stromal CD10 expression	Poor prognosis, estrogen receptor negativity, high grade	[35, 43]
Melanomas	High CD10 expression	Advanced stage, higher metastasis	[44, 45]
Follicular papillary thyroid cancer	High CD10 expression	Bad	[46]
Papillary thyroid cancer	High CD10 expression	Advanced stage	[47]
Adenocarcinoma of stomach and colon	Decreased CD10 expression	Poor differentiation	[13]
Head and neck squamous cell carcinoma	Increased CD10 expression	Therapeutic resistance	[44]
Colorectal cancer	Increased CD10 expression	Higher invasion	[25]
Colorectal cancer	Serum CD10 expression	Liver metastasis	[28]
Esophageal squamous cell carcinoma	Upregulated CD10 expression	Poor disease-free survival and overall survival	[29]
Pancreatic endocrine tumors	Membranous expression of CD10	Poor differentiation, high proliferative index, low microvascular density, large tumor size, metastasis, poor survival	[36]
Cervical carcinoma	Decreased CD10 expression	Higher proliferation and invasion	[52]
Ovarian carcinoma	Increased CD10 expression	Suppressing progressive potential	[53]
Gastric carcinoma	Stromal cells CD10 expression	Differentiated carcinoma, high depth of invasion, lymph node metastasis	[40]